4D Molecular Therapeutics...
(FDMT)
undefined
undefined%
At close: undefined
6.50
0.15%
After-hours Dec 13, 2024, 04:15 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue,
expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | 20.72M | 3.13M | 18.04M | 13.61M | 6.99M | 14.13M | 5.79M |
| Cost of Revenue | 97.10M | 3.88M | 3.02M | 53.04M | 38.72M | 18.36M | 13.57M |
| Gross Profit | -76.37M | -751.00K | 15.02M | -39.43M | -31.73M | -4.23M | -7.78M |
| Operating Income | -112.87M | -110.03M | -71.33M | -56.66M | -50.76M | -10.40M | -11.27M |
| Interest Income | 12.21M | 2.57M | 137.00K | 152.00K | 1.50M | 850.00K | 89.00K |
| Pretax Income | -100.84M | -107.49M | -71.32M | -56.69M | -49.31M | -9.55M | -11.22M |
| Net Income | -100.84M | -101.08M | -68.30M | -56.54M | -52.94M | -9.55M | -11.22M |
| Selling & General & Admin | 36.49M | 32.91M | 28.01M | 17.24M | 13.89M | 6.17M | 3.49M |
| Research & Development | 97.10M | 80.25M | 61.36M | 53.04M | 38.72M | 18.36M | 13.57M |
| Other Expenses | - | 2.54M | 16.00K | -181.00K | -46.00K | -2.00K | -40.00K |
| Operating Expenses | 133.59M | 113.16M | 89.37M | 70.28M | 52.61M | 24.53M | 17.06M |
| Interest Expense | - | - | - | - | - | - | - |
| Selling & Marketing Expenses | - | - | - | - | - | - | - |
| Cost & Expenses | 133.59M | 113.16M | 89.37M | 70.28M | 52.61M | 24.53M | 17.06M |
| Income Tax | - | -6.42M | -3.02M | -152.00K | 3.63M | 848.00K | -89.00K |
| Shares Outstanding (Basic) | 39.13M | 32.35M | 27.73M | 26.68M | 26.49M | 12.52M | 14.84M |
| Shares Outstanding (Diluted) | 39.13M | 32.35M | 27.73M | 26.68M | 26.49M | 12.52M | 14.84M |
| EPS (Basic) | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
| EPS (Diluted) | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
| EBITDA | -107.12M | -106.15M | -68.31M | -55.22M | -44.62M | -9.70M | -10.65M |
| Depreciation & Amortization | 5.75M | 3.88M | 3.02M | 1.44M | 1.00M | 697.00K | 626.00K |